Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude
- PMID: 14606102
- PMCID: PMC4656546
- DOI: 10.3748/wjg.v9.i11.2583
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude
Abstract
Aim: To study the effect of rabeprazole (RAB) on nocturnal acid breakthrough (NAB) and nocturnal alkaline amplitude (NAKA) and to compare it with omeprazole (OME) and pantoprazole (PAN).
Methods: By an open comparative study, forty patients with active peptic ulcer were randomly assigned to receive one of the three PPIs (proton pump inhibitor) with a single oral dose. They were divided into RAB group (10 mg), OME group (20 mg) and PAN group (40 mg). Twenty healthy volunteers were enrolled to the control group (without taking any drug). Intragastric pH monitoring was then performed 1 hour before and 24 hours after the dose was given.
Results: No clinically undesirable signs and symptoms possibly attributed to the administration of RAB or OME and PAN were recognizable throughout the study period. All subjects completed the study according to the protocol. All data were processed by a computer using the Student t test or t' test followed by an analysis of covariance. P<0.05 was considered to have statistical significance. The intragastric pH of NAB was significantly higher in RAB group (1.84+/-0.55) than in either OME group (1.15+/-0.31) or PAN group (1.10+/-0.30) (both P<0.01). RAB produced a longer sustaining time (4.65+/-1.22 h) on NAKA than OME (3.22+/-1.89 h) (P<0.05), PAN (3.15+/-1.92 h) (P<0.05), and the sustaining time of NAKA in RAB group was longer than that in the healthy control group (P<0.01) too. In addition, RAB produced a much higher pH on NAKA (6.41+/-0.45) in comparison with PAN (6.01+/-0.92) (P<0.05).
Conclusion: A single oral dose of 10 mg RAB may increase the pH of NAB and shorten the sustaining time of NAB, and it may increase the pH of NAKA as well as prolong the sustaining time of NAKA.
Figures
Similar articles
-
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.Eur J Clin Pharmacol. 2004 Oct;60(8):531-9. doi: 10.1007/s00228-004-0804-6. Epub 2004 Sep 2. Eur J Clin Pharmacol. 2004. PMID: 15349707 Clinical Trial.
-
[The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].Zhonghua Nei Ke Za Zhi. 2003 Nov;42(11):777-80. Zhonghua Nei Ke Za Zhi. 2003. PMID: 14636465 Clinical Trial. Chinese.
-
[The effect of rabeprazole on gastric pH in patients with gastric ulcer].Zhonghua Nei Ke Za Zhi. 2004 Sep;43(9):675-8. Zhonghua Nei Ke Za Zhi. 2004. PMID: 15504308 Clinical Trial. Chinese.
-
What is potent acid inhibition, and how can it be achieved?Drugs. 2005;65 Suppl 1:13-23. doi: 10.2165/00003495-200565001-00004. Drugs. 2005. PMID: 16335854 Review.
-
[All proton pump inhibitors are equally efficacious in standard dosages].Lakartidningen. 2003 Jun 19;100(25):2212-6. Lakartidningen. 2003. PMID: 12872509 Review. Swedish.
Cited by
-
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research.Expert Opin Drug Metab Toxicol. 2023 Jan;19(1):1-11. doi: 10.1080/17425255.2023.2178897. Epub 2023 Feb 18. Expert Opin Drug Metab Toxicol. 2023. PMID: 36800927 Free PMC article. Review.
-
Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.Gut Liver. 2008 Jun;2(1):30-8. doi: 10.5009/gnl.2008.2.1.30. Epub 2008 Jun 30. Gut Liver. 2008. PMID: 20485608 Free PMC article.
-
Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.BMC Gastroenterol. 2014 Jul 15;14:128. doi: 10.1186/1471-230X-14-128. BMC Gastroenterol. 2014. PMID: 25027286 Free PMC article. Clinical Trial.
-
A review of rabeprazole in the treatment of acid-related diseases.Ther Clin Risk Manag. 2007 Jun;3(3):363-79. Ther Clin Risk Manag. 2007. PMID: 18488081 Free PMC article.
References
-
- Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol. 2001;13 Suppl 1:S29–S33. - PubMed
-
- Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol. 2001;13 Suppl 1:S35–S41. - PubMed
-
- Gong J, Zhu YL, Luo JY, Wang XQ. The acid-inhibiting effect of famotidine with a single dose by injection in musle. Zhonghua Yixue Zazhi. 1998;37:762–765.
-
- Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93:763–767. - PubMed
-
- Bianco A, Cagossi M, Piraccini R, Castrucci G, Greco AV. The nightly spontaneous alkalinization of the stomach. Riv Eur Sci Med Farmacol. 1993;15:17–27. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical